Goicoechea (2020)
COVID-19: Clinical course and outcomes of 36 maintenance hemodialysis patients from a single center in Spain
https://doi.org/10.1016/j.kint.2020.04.031
https://www.kidney-international.org/article/S0085-2538(20)30509-3/pdf
Patient characteristics
Age (1 year increase vs. Not applicable)
COVID-19 (death)
Hazard ratio: 1.064 (0.996-1.138) Adjusted model

Spain

Retrospective observational study

Medical records

36

Thirty-six maintenance hemodialysis (MHD) patients out of 282 followed in 2 reference hemodialysis units were hospitalized with confirmed coronavirus disease 2019 (COVID-19) starting on March 12, 2020.

The age of the patients was 71 + or - 12 years (range, 29–90 years), and 64% were male. A total of 12 patients required assisted mechanical ventilation, but only one patient was admitted to the ICU, due to severe comorbidities in the other 11 patients that limited invasive measures. All patients were included in MHD programs with a median time on dialysis therapy of 29 months (1 week–285 months). Treatment : Twenty-seven patients received lopinavir/ ritonavir for antiviral therapy. Hydroxychloroquine was administered in all patients but one. Azithromycin was administered in 23 patients, corticosteroids in 17, interferon b in 13, and tocilizumab in 2.

Total

30 Day


COVID-19 (death)

11

Among the 36 patients, 18 had worsening of their clinical status. 11 of those 18 patients died during hospitalization, all due to respiratory failure.


Patient characteristics

Age

36 patients aged 29–90 years

Not applicable

1 year increase


Hazard ratio

1.064 (0.996-1.138)

No

No

Yes

age, corticosteroid treatment


Treatment scheme - Model 4

Average

Yes